India's Piramal adds capacity to U.S. high-potency API site

With an expansion, Piramal Pharma Solutions can now make HPAPIs with OELs down to 1mcg/m3 at the site it acquired from Ash Stevens. ( Ash Stevens )

India’s Piramal has intensified its focus on the U.S. market including buying an API producer in the Michigan several years ago. Now its CDMO, Piramal Pharma Solutions, has completed an expansion at that site where it makes high-potency active pharmaceutical ingredients (HPAPIs).

The company invested $10 million in the former Ash Stevens site in Riverview, Michigan, where it makes HPAPis with low exposure levels, adding two kilo labs as well as quality control and analysis labs. It is now capable of making HPAPIs with OELs down to 1mcg/m3.  

It has added nearly 50 jobs. It has 127 workers now but says it plans to soon have 150. 


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

RELATED: Piramal bulks up in injectable generics, buying five drugs from J&J

“This new, enhanced capability opens the site up to a new base of customers, including the antibody drug conjugate (ADC) market,” Vince Ammoscato, Piramal VP and site head at Riverview, said in a statement

With demand for high-potency APIs growing, other CDMOs are scaling up in that arena as well. Cambrex in May opened new capacity at a site in Iowa. It can handle projects up to 300 kg. 

Piramal bought the Ash Stevens operations in 2016 for $53 million and milestones


Suggested Articles

For just the second time, the DOJ indicted an opioid distributor for its role in illegally pushing pills at the height of the addiction epidemic.

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.

When AstraZeneca sold its Avlon, England plant in 2016, it thought its liabilities were over. Former employees said the drugmaker broke its promises.